• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
PLX4720

PLX4720

Product ID P4492
Cas No. 918505-84-7
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $132.60 In stock
25 mg $368.20 Please Inquire
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

PLX4720 is an orally available ATP-competitive kinase inhibitor specific for mutant (V600E) B-Raf, which is present in a variety of cancer subtypes. PLX4720 is an analog of vemurafenib. This compound is being examined as a treatment for unresectable or metastatic melanomas. Inhibition of B-Raf by PLX4720 induces apoptosis and autophagy in tumor cells, resulting in decreased tumor growth and increased survival in vitro and in vivo. Additional downstream effects of B-Raf inhibition by PLX4720 include downregulation of expression of angiogenic factors, enhancement of surface expression of tumor-associated antigens on tumor cells, and alterations of trafficking of local immune cells such as CD8+ T lymphocytes.

Product Info

Cas No.

918505-84-7

Purity

≥98%

Formula

C17H14ClF2N3O3S

Formula Wt.

413.83

Chemical Name

N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2, 4-difluorophenyl]propane-1-sulfonamide

IUPAC Name

N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2, 4-difluorophenyl]propane-1-sulfonamide

Synonym

PLX-4720

Solubility

DMSO 83 mg/mL (200.56 mM) Water Insoluble Ethanol Insoluble

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

P4492 MSDS PDF

Info Sheet

P4492 Info Sheet PDF

References

Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15;19(2):393-403. PMID: 23204132.

Bottos A, Martini M, Di Nicolantonio F, et al. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):E353-9. PMID: 22203991.

Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012 Mar 1;18(5):1386-94. PMID: 22156613.

Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010 Jul 1;70(13):5213-9. PMID: 20551059.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • N3452

    Nimustine Hydrochloride

    Nitrosourea, DNA cross-linker.

    ≥97%
  • G2869

    Ghrelin, rat

    Endogenous peptide hormone, involved in feeding...

    ≥95%
  • G0668

    GBR 12935 Dihydrochloride

    DAT inhibitor.

    ≥98%
  • F1650

    Fenbendazole

    Benzimidazole; microtubule polymerization inhib...

    ≥98%
  • Z1216

    Z-DEVD-AMC

    Caspase substrate.
    ≥95%
  • A9435

    Axitinib

    VEGFR inhibitor.

    ≥98%
  • B8276

    Butyric Acid Sodium

    HDAC inhibitor, RNA splicing modulator.

    ≥98%
  • L493400

    LMK-235

    Selective HDAC4 and HDAC5 inhibitor.

    ≥98%
  • C6818

    Crenolanib

    FLT3, PDGFR inhibitor.

    ≥98%
  • S8010

    [Nle11]-Substance P

    Endogenous tachykinin peptide, involved in infl...

    ≥95%
  • S7061

    SRPIN340

    SRPK1 inhibitor.

    ≥98%
  • C577524

    Concanamycin A

    Macrolide lactone antibiotic.

    ≥98%
  • P577520

    Ponatinib

    pan-Bcr-Abl tyrosine kinase inhibitor.

    ≥99%
  • S1607

    Secretin, rat

    Endogenous peptide hormone, involved in feeding...

    ≥95%
  • P1853

    Penicillin V Potassium

    Hydrophobic β-lactam; penicillin binding prote...

    ≥98%
  • T0251

    Tamsulosin Hydrochloride

    α1-adrenergic antagonist.

    ≥98%
  • D3362

    Dipyridamole

    PDE and adenosine deaminase inhibitor.

    ≥98%
  • C0175

    Carbetocin Acetate

    Peptide, oxytocin analog; potential OXTR agonis...

    ≥95%
  • O9201

    Oxaliplatin

    Pt-based DNA cross-linker.

    ≥98%
  • H0207

    Hepatitis B Virus Core Protein (128-140)

    B cell epitope found on hepatitis B viral core ...

    ≥95%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only